ArticlePatient preference and adherence2026
Acceptance of Cell and Gene Therapy Among Patients with Hematological Diseases in China: A Cross-Sectional Study.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cell and gene therapy (CGT) offers breakthrough solutions for hematological diseases. Patient acceptance is a key determinant of its successful clinical translation. This study investigates CGT acceptance among hematological patients and explores its primary determinants. Methods: A cross-sectional study was conducted (June-July 2025) with 385 hematological patients at a single specialized hematology center (Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences). Each participant completed a sociodemographic and clinical questionnaire, the Risk Perception Assessment Scale for Patients with Hematological Diseases, and the EuroQol 5-Dimensional 5-Level (EQ-5D-5L) questionnaire. Correlation and multivariable ordinal logistic regression analyses were performed using SPSS 26.0. Results: Most patients (76.6%) were cautious toward CGT. Risk perception ( Conclusion: Enhancing CGT acceptance among patients with hematological diseases may be facilitated through tailored educational interventions and expanded financial support. However, further multicenter and prospective studies are required to validate these cross-sectional associations and evaluate the actual effectiveness of specific interventions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.